METHODS AND SYSTEMS FOR FUNCTIONAL MATURATION OF iPSC AND ESC DERIVED CARDIOMYOCYTES
US-2024076619-A1 · Mar 7, 2024 · US
Genetically modified muscle cells which express neurotrophic factors
US10744162B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10744162-B2 |
| Application number | US-201916353680-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2019 |
| Priority date | Mar 3, 2011 |
| Publication date | Aug 18, 2020 |
| Grant date | Aug 18, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated cell population, comprising at least four subpopulations of human muscle progenitor cells, each of the at least four subpopulations being distinct in that they are genetically modified to express a different neurotrophic factor, wherein the neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). 2. The isolated cell population of claim 1 , wherein said muscle progenitor cells comprise skeletal muscle progenitor cells. 3. The isolated cell population of claim 1 , wherein each of said at least four subpopulations are present in substantially equal amounts. 4. The isolated cell population of claim 1 , wherein each of said at least four subpopulations is genetically modified to express a single neurotrophic factor.
Assignees
Inventors
Classifications
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins · CPC title
- A61K35/34Primary
Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44) · CPC title
Insulin-like growth factors [IGF] · CPC title
Vascular endothelial growth factor [VEGF] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10744162B2 cover?
- An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrop…
- Who is the assignee on this patent?
- Ramot At Tel-Aviv Univ Ltd, Yeda Res & Dev
- What technology area does this patent fall under?
- Primary CPC classification A61K35/34. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).